CERo Therapeutics Holdings (CERO) said Friday that the US Food and Drug Administration has cleared its investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.
The company said it expects to start the phase 1 trial in Q1 of 2025.
CERo's shares soared past 79% in recent trading.
Price: 0.34, Change: +0.15, Percent Change: +79.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments